Euronext et Biotech Bourse lancent le premier baromètre trimestriel de la biotech


  • The “Biotech Barometer" highlights listed biotech companies
  • A quarterly review designed to identify market trends
  • Barometer reveals renewed interest in biotech stocks despite cautious market segment in Q4 2016

Amsterdam, Brussels, Lisbon, London and Paris – 2 February 2017 – Euronext today published its first “Biotech Barometer”, a new quarterly tool that offers an insight into major trends in biotechnology companies[1] listed on Euronext markets. Designed in partnership with Biotech Bourse, the barometer shows performance indicators, investor interest and market sentiment specifically for this sector.

Highlighting biotech
Biotech is a key sector for Euronext: between 2012 and 2016 the number of biotech companies listed on its markets rose from 12 to 45, with a market capitalisation of nearly €12 billion. The Biotech Barometer is designed to showcase this fast-moving sector. In addition to providing information to biotech companies—both listed and unlisted—it will help CEOs assess their momentum against a broader benchmark and give ordinary investors a simple guide to tracking market trends.

The quarterly publication is underpinned by data and innovative tools developed by Biotech Bourse and Euronext’s Post-Listing Services. The Biotech Barometer includes:

  • Trends in market statistics—prices, volumes and indexes 
  • A market sentiment indicator
  • Institutional investor interest (number, capital invested, region of origin)
  • Key performance indicators for the biotech industry: companies’ cash positions, calls on the market, treatment areas and published clinical results.

Key findings of first Biotech Barometer
Although market sentiment remained cautious, Euronext and Biotech Bourse found that interest in biotech stocks rallied in Q4 2016. Specific findings:

  • Trading volumes rose. December was the sector’s fourth best month in 2016: trading in the 45 Euronext-listed biotech stocks covered by the Barometer generated over €46 million daily.
  • Some 140 new institutional investors bought shares in the 45 biotech companies, producing capital inflows of over €600 million. While 75% of these investors were based in Europe, 20% were in North America and 5% were in Asia.
  • The rate of calls on the market increased: the 45 Biotech companies listed on Euronext markets raised €214 million in Q4, up 75.2% over the previous quarter. In total they raised over €1 billion in 2016 (primary and secondary issues combined)
  • At year-end 2016, some 330 institutional investors were identified as holding positions in the 45 biotech companies, with combined holdings of over €3 billion and two-thirds of that total from Europe.

To browse Biotech Barometer, visit Euronext Tech Corner. Join the conversation on social media using the hashtag  #BiotechBarometer.


[1] Includes only companies offering diagnostics and therapies

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.